By Jo Cavallo Posted: 1/15/2021 1:11:00 PM Last Updated: 1/15/2021 3:03:01 PM Electronic health record–based artificial intelligence may help uncover new risk factors in the development of early-onset colorectal cancer, according to study findings presented by Parker et al at…
In a Belgian phase III trial (ROBOMET) reported in the Journal of Clinical Oncology, Mercier et al attempted to determine whether dose-escalated, single-fraction stereotactic body…
In a study reported in JAMA Oncology, Heyward et al examined the harm-benefit balance of immune checkpoint inhibitor use across lines of treatment in non–small…
At just 5 years old, Charu Aggarwal, MD, MPH, FASCO, already knew that she wanted to be a physician when she grew up, although she…
In a Danish Breast Cancer Group nationwide prospective cohort study reported in The Lancet Oncology, Jensen et al attempted to develop a prognostic standard mortality…
At just 5 years old, Charu Aggarwal, MD, MPH, FASCO, already knew that she wanted to be a physician when she grew up, although she…
At just 5 years old, Charu Aggarwal, MD, MPH, FASCO, already knew that she wanted to be a physician when she grew up, although she…
With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to…
Zongertinib, an investigational oral, HER2-selective, EGFR-sparing tyrosine kinase inhibitor, elicited durable responses and demonstrated clinical benefit in patients with advanced, previously treated…
Results from the global phase III IMforte trial found that maintenance therapy with a combination of the alkylating agent lurbinectedin and the PD-L1 inhibitor atezolizumab…
In a phase II trial reported in the Journal of Clinical Oncology, Chen et al attempted to determine whether there is a benefit to adding…
